Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

236P - Trastuzumab deruxtecan in italian real-world experience: updated analysis from DE-REAL study

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Andrea Botticelli

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101223-101223. 10.1016/esmoop/esmoop101223

Authors

A. Botticelli1, S. Pisegna2, S. Scagnoli2, D. Santini3, M. De Laurentiis4, R. Caputo5, R. Scafetta6, M. Palleschi7, A. Orlandi8, Z. Ballatore9, M. Giampaglia10, A. Chiavassa11, D. Alesini12, L. Rossi13, M.A. Fabbri14, G. D'Auria15, P. Vici16, L. Strigari17, P. Marchetti18, A. Fabi8

Author affiliations

  • 1 AOU Sant'Andrea, Rome/IT
  • 2 Sapienza University of Rome, Rome/IT
  • 3 Università degli Studi di Roma la Sapienza - Facoltà di Medicina, Roma/IT
  • 4 Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Università degli Studi di Napoli ”Federico II”, Napoli/IT
  • 5 Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Università degli Studi di Napoli ”Federico II”, 80131 - Napoli/IT
  • 6 Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT
  • 7 IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola/IT
  • 8 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome/IT
  • 9 AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Torrette di Ancona/IT
  • 10 Azienda Ospedaliera Regionale S. Carlo di Potenza, Potenza/IT
  • 11 Sapienza Università di Roma, Rome/IT
  • 12 Ospedale Santo Spirito, Roma/IT
  • 13 Ospedale Santa Maria Goretti - Pronto Soccorso, Latina/IT
  • 14 Ospedale Belcolle - ASL Viterbo, Viterbo/IT
  • 15 Unità di Neonatologia, Patologia e Terapia Intensiva Neonatale, Rome/IT
  • 16 IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome/IT
  • 17 University of Bologna - Alma Mater Studiorum, Bologna/IT
  • 18 Istituto Dermopatico dell'Immacolata IRCCS, 161 - Rome/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 236P

Background

Trastuzumab deruxtecan (TDXd) demonstrated unprecedented efficacy in patients (pts) with HER2+ metastatic breast cancer after at least a prior anti-HER2 regimen. However, few data are available about its efficacy in routine clinical practice. In this multicenter retrospective study we evaluated effectiveness and safety of TDXd in a real-world (rw) population.

Methods

Clinical and pathological information about pts with HER2+ mBC who received TDXd were collected from 11 italian hospitals. Activity and toxicity were evaluated following RECIST 1.1 and CTCAE v5 criteria. The survival outcomes evaluation included PFS, milestone-PFS and OS.

Results

One hundred forty-three patients were enrolled. Median age was 66 (range 33-84) and 4 men were included. Estrogen receptor (HR) was positive in 108 (75%) pts and negative in 35 (25%). TDXd was administered as first, second, third or subsequent line in 4 (3%), 16 (11%), 42 (29%), and 81 (57%) pts respectively. Among 123 pts with measurable disease, the ORR was 68% and the disease control rate was 91% (9 CRs, 74 PRs, and 30 SD). Nine (7%) pts had primary resistance to TDXd. With a median follow-up of 12 months (range: 1-31), the mPFS was 16 months. PFS was 84%, 59%, and 39% at 6, 12, and 18 months, respectively. A favorable trend in PFS was reported in pts receiving TDXd as I/II line vs further lines, though the difference did not reach statistical significance (17 vs 15 months, 76% vs 56%; p=0.098). OS was 90.8% at 6 months, 74% at 12, and 59% at 18 months, respectively. Median OS was 20 months. 89% of pts who received TDXd as I/II line were alive at 12 months vs 73% of subsequent lines (p=0.39). Any-grade toxicity was registered in 84 patients (59%). The most common toxicities reported were nausea (33%), neutropenia (21%), and asthenia (21%). Liver toxicity and diarrhea were uncommon (5%, and 1% respectively). Severe toxicities were registered in 18% of pts and the most frequent were neutropenia, nausea/vomiting, and interstitial lung disease observed in 15, 2 and 3 pts, respectively. Adverse events led to dose reduction in 37 pts (26%).

Conclusions

The efficacy and safety of TDXd were confirmed in an unselected real-world population. These results are consistent with the registrative trials and no new safety concerns were reported.

Legal entity responsible for the study

Andrea Botticelli.

Funding

Has not received any funding.

Disclosure

A. Botticelli: Financial Interests, Personal, Advisory Board: Roche, Novartis, MSD, Lilly, Pfizer, Amgen, BMS, Gilead; Financial Interests, Personal, Invited Speaker: Sofos. S. Pisegna: Financial Interests, Personal, Invited Speaker: Eli Lilly, Novartis, Pfizer, Roche, AstraZeneca. S. Scagnoli: Financial Interests, Personal, Invited Speaker: Novartis, Lilly, MSD, Pfizer, BMS. M. De Laurentiis: Financial Interests, Personal, Speaker’s Bureau: Roche, Celgene, MSD; Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Eisai, Exact Science, Gilead, Novartis, Pfizer, Pierre Fabre, Roche; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Eli Lilly, Seagen. R. Caputo: Financial Interests, Personal, Invited Speaker: Roche, Eli Lilly, MSD, Gilead, Daiichi; Financial Interests, Personal, Advisory Board: Novartis, Pierre-Fabre. M. Palleschi: Financial Interests, Personal, Advisory Board: Novartis, Lilly. A. Orlandi: Financial Interests, Personal, Invited Speaker: Amgen, Pfizer, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Lilly, Novartis, Gilead. M. Giampaglia: Financial Interests, Personal, Invited Speaker: Novartis, Eli Lilly. M.A. Fabbri: Financial Interests, Personal, Invited Speaker: Eli Lilly, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Roche, Gilead. G. D'Auria: Financial Interests, Personal, Advisory Board: Eisai, Amgen, Pfizer, Lilly, Novartis. P. Vici: Financial Interests, Personal, Advisory Board: Novartis, Pfizer; Financial Interests, Personal, Invited Speaker: Eli Lilly, Eisai. P. Marchetti: Financial Interests, Personal, Advisory Role: BMS, Roche, Genentech, MSD, Novartis, Amgen, Merck, Pierre Fabre, Incyte. A. Fabi: Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Gilead, Sophos, Seagen, AstraZeneca, Lilly, Pierre Fabre, Exact Science. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.